Impact of CYP2D6 Genetic Polymorphism on Tramadol Pharmacokinetics and Pharmacodynamics-Reference-Cited by-同舟云学术

Impact of CYP2D6 Genetic Polymorphism on Tramadol Pharmacokinetics and Pharmacodynamics

Published:2007-05 Issue:3 Volume:11 Page:171-181
ISSN:1177-1062
Container-title:Molecular Diagnosis & Therapy
language:en
Short-container-title:Mol Diag Ther

Author:

Hua Gan Siew,Ismail Rush,Adnan Wan Aasim Wan,Zulmi Wan

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology,Genetics,Molecular Medicine,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/BF03256239.pdf

Reference46 articles.

1. Raffa RB, Friderichs E, Reimann W, et al. Opioid and non-opioid components independently contribute to the mechanism of action of tramadol, an “atypical” opioid analgesic. J Pharmacol Exp Ther 1992; 260: 275–85

2. Lewis KS, Han NH. Tramadol: a new centrally-acting analgesia. Am J Health Syst Pharm 1997; 54: 643–52

3. Lee R, McTavish D, Sorkin EM. Tramadol: a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in acute and chronic pain states. Drugs 1993; 46: 313–40

4. Eichelbaum M, Evert B. Influence of pharmacogenetic on drug disposition and response. Clin Exp Pharmacol Physiol 1996; 23: 983–5

5. Meyer UA, Zanger UM. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 1997; 37: 269–96

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Extracellular vesicles as the next‐generation modulators of pharmacokinetics and pharmacodynamics of medications and their potential as adjuvant therapeutics;Clinical and Translational Medicine;2024-08

2. From Drug Discovery to Drug Approval: A Comprehensive Review of the Pharmacogenomics Status Quo with a Special Focus on Egypt;Pharmaceuticals;2024-07-03

3. Neuropathic pain: Mechanisms and therapeutic strategies;Frontiers in Cell and Developmental Biology;2023-01-16

4. Tramadol as an analgesic;Treatments, Mechanisms, and Adverse Reactions of Anesthetics and Analgesics;2022

5. Consensus multidisciplinaire de l’intergroupe SFETD/SFGG sur l’utilisation des opioïdes dits faibles dans la prise en charge de la douleur chez la personne âgée;Douleur et Analgésie;2021-12